Friday, July 10, 2026

pharma · Colitis, Ulcerative · Multiple Myeloma

Janssen Cilag International

Janssen Cilag International clinical programs — 21 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

São Paulo, EU HQ
13 Employees
EMA registrant Type
Company details
Status
Public
HQ
São Paulo, EU
Employees
13
Programs
46
Drugs
37
Patents
0
Intelligence · Clinical Programs

Janssen Cilag International projects

21 ClinicalTrials.gov programs sponsored by Janssen Cilag International.

Janssen Cilag International has 21 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Amivantamab

    Janssen Cilag International NV

    Colorectal Neoplasms

    phase 3 mab active

    1 trial
  2. Apalutamide

    Janssen Cilag International NV

    Metastatic Castrate-sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial
  3. Canagliflozin

    Janssen Cilag International NV

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial
  4. Cilta-cel

    Janssen Cilag International NV

    Multiple Myeloma

    phase 3 small molecule active

    1 trial
  5. Dara SC

    Janssen Cilag International NV

    Multiple Myeloma

    phase 3 small molecule completed

    1 trial
  6. Daratumumab

    Janssen Cilag International NV

    Multiple Myeloma

    phase 3 small molecule active

    3 trials
  7. Esketamine

    Janssen Cilag International NV

    Depressive Disorder, Major

    phase 3 small molecule completed

    1 trial
  8. Glimepiride

    Janssen Cilag International NV

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial
  9. Golimumab 1 mg per kg

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 3 small molecule terminated

    1 trial
  10. Guselkumab Dose 1

    Janssen Cilag International NV

    Crohn's Disease

    phase 3 small molecule active

    1 trial
  11. Ibrutinib

    Janssen Cilag International NV

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial
  12. Icotrokinra

    Janssen Cilag International NV

    Crohn Disease

    phase 3 small molecule active

    1 trial
  13. JNJ-77242113

    Janssen Cilag International NV

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial
  14. LHRHa

    Janssen Cilag International NV

    Prostatic Neoplasms

    phase 3 small molecule active

    1 trial
  15. Nipocalimab

    Janssen Cilag International NV

    Sjogrens Syndrome

    phase 3 small molecule active

    1 trial
  16. Olanzapine

    Janssen Cilag International NV

    Bipolar Disorder

    phase 3 small molecule completed

    1 trial
  17. Paliperidone palmitate

    Janssen Cilag International NV

    Schizophrenia

    phase 3 small molecule completed

    2 trials
  18. Pimodivir 600 mg

    Janssen Cilag International NV

    Influenza A

    phase 3 small molecule terminated

    1 trial
  19. Rituximab

    Janssen Cilag International NV

    Chronic Lymphocytic Leukemia

    phase 3 small molecule completed

    1 trial
  20. Tapentadol IR 50 mg

    Janssen Cilag International NV

    Hallux Valgus

    phase 3 small molecule completed

    1 trial
  21. Ustekinumab Dose Based on BSA and Body Weight

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Janssen Cilag International have?

21 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.